RAY1216 clinical trials
How each study uses RAY1216 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RAY1216
- 1
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses RAY1216 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in ChinaCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT06362460Written as [14C] RAY1216How we know
- Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19CompletedPhase 3Guangdong Raynovent Biotech Co., LtdNCT05620160Written as RAY1216How we know
- The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult ParticipantsCompletedPhase 1Guangdong Raynovent Biotech Co., LtdNCT05829551Written as RAY1216 dose 1How we know